PMC:4608092 / 36598-37853 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4608092","sourcedb":"PMC","sourceid":"4608092","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4608092","text":"Figure 13 Effects of IFN-β on RNF213 protein expression and antiangiogenic activity in iPSECs from control subjects (GG genotype) and MMD patients (AA genotype). A, RNF213 mRNA levels in iPSECs treated with IFN-β for 24 hours. Fold induction attributed to IFN-β was compared with activity at 0 ng/mL of IFN-β. A column with a bar represents mean±SD of 2 controls (blue) or 2 patients (red) in 3 independent experiments. *P\u003c0.05, according to Student t test comparing 0 ng/mL of IFN-β in control (blue) iPSECs at 0.1, 1, or 10 ng/mL. #P\u003c0.05, according to Student t test comparing 0 ng/mL of IFN-β in patient (red) iPSECs at 0.1, 1, or 10 ng/mL. B, Representative photomicrographs (right panel) and quantified tubal area (left panel) of HUVECs and iPSECs treated with IFN-β. Scale bars indicate 100 μm. HUVECs without IFN-β treatment served as the positive control (100%). A column with a bar represents mean±SD of 2 controls or 2 patients in 3 independent experiments. *P\u003c0.05 according to Student t test comparing 0 ng/mL of IFN-β within HUVECs, control iPSECs, or patient iPSECs. HUVECs indicates human umbilical vein endothelial cells; IFN, interferon; iPSECs, induced pluripotent stem cell-derived vascular endothelial cells; MMD, moyamoya disease.\nF","tracks":[]}